

Sarah Gooding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3137411/publications.pdf>

Version: 2024-02-01

17
papers

302
citations

1163117

8
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

574
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. British Journal of Haematology, 2022, 197, 293-301.	2.5	16
2	Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. Frontiers in Genetics, 2022, 13, 831779.	2.3	5
3	Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1) Tj ETQq1 1 0,784314 ggBT /Ov	1.9	5
4	Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, .		0
5	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2854-2864.	7.0	6
6	Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood, 2021, 137, 232-237.	1.4	90
7	Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. EJHaem, 2021, 2, 809.	1.0	3
8	Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. Blood, 2021, 138, 458-458.	1.4	1
9	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Ibrandomide-Treated Myeloma Patients. Blood, 2021, 138, 730-730.	1.4	4
10	A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma. Blood, 2021, 138, 2676-2676.	1.4	1
11	Gremlin 1 " small protein, big impact: the multiorgan consequences of disrupted BMP antagonism ". Journal of Pathology, 2020, 251, 349-352.	4.5	4
12	Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease. Nature Communications, 2019, 10, 4533.	12.8	46
13	Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. Nature Communications, 2017, 8, 403.	12.8	45
14	New approaches to targeting the bone marrow microenvironment in multiple myeloma. Current Opinion in Pharmacology, 2016, 28, 43-49.	3.5	25
15	Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders. Journal of Allergy and Clinical Immunology, 2015, 136, 487-490.e2.	2.9	20
16	Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLoS ONE, 2015, 10, e0136207.	2.5	10
17	Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. Journal of Infection, 2007, 54, e169-e174.	3.3	22